Bad Blood [正版]Bad Blood 英文原版 恶血 坏血 硅谷独角兽的骗局 滴血成金 比尔盖茨 平装 女版乔

         店铺公告

  为保障消费者合理购买需求及公平交易机会，避免因非生活消费目的的购买货囤积商品，抬价转售等违法行为发生，店铺有权对异常订单不发货且不进行赔付。异常订单：包括但不限于相同用户ID批量下单，同一用户（指不同用户ID，存在相同/临近/虚构收货地址，或相同联系号码，收件人，同账户付款人等情形的）批量下单（一次性大于5本），以及其他非消费目的的交易订单。

温馨提示：请务必当着快递员面开箱验货，如发现破损，请立即拍照拒收，如验货有问题请及时联系在线客服处理，（如开箱验货时发现破损，所产生运费由我司承担，一经签收即为货物完好，如果您未开箱验货，一切损失就需要由买家承担，所以请买家一定要仔细验货），

关于退货运费：对于下单后且物流已发货货品在途的状态下，原则上均不接受退货申请，如顾客原因退货需要承担来回运费，如因产品质量问题（非破损问题）可在签收后，联系在线客服。

  本店存在书、古旧书、收藏书、二手书等特殊商品，因受采购成本限制,可能高于定价销售，明码标价，介意者勿拍!

1.书籍因稀缺可能导致售价高于定价,图书实际定价参见下方详情内基本信息,请买家看清楚且明确后再拍，避免价格争议!

2.店铺无纸质均开具电子，请联系客服开具电子版

书名：Bad Blood: Secrets and Lies in a Silicon Valley Startup坏血：一个硅谷巨头的秘密与谎言
作者：John Carreyrou
出版社名称：Knopf
出版时间：2018
语种：英文
ISBN：9781524711481
商品尺寸：15.5 x 2.8 x 23.4 cm
包装：平装
页数：352（以实物为准）

★两度获得普利策新闻奖的作者约翰·卡雷鲁
★引爆欧美阅读热潮的畅销书，比尔·盖茨力荐
★《纽约时报》、《时代周刊》、《华尔街日报》、《华盛顿邮报》年度图书
★改编为同名电影，由奥斯卡影后詹尼佛·劳伦斯主演

她，被誉为“女版乔布斯”，用“一滴血”颠覆血液检测、翻转医疗产业；短短十年，成为硅谷身价数十亿美元的女性科技创业家。然而，一个爆料、一封匿名检举信，一位《华尔街日报》调查记者，在六个月内，却使这高达90亿美元的生物科技独角兽极速崩解……

在本书Bad Blood: Secrets and Lies in a Silicon Valley Startup《坏血：一个硅谷巨头的秘密与谎言》中，作者约翰·卡雷鲁揭露了继“安然事件”之后规模极为庞大的企业诈欺案件，讲述了一个关于野心与被利益蒙蔽双眼的故事。

媒体评论：
“这个故事比我想象的还要疯狂，我发现自己一开始就无法放下它。这本书涵盖了一切：精心策划的骗局、企业阴谋、杂志封面故事、被毁坏的家庭关系，以及一家曾经价值近100亿美元的公司的崩溃。”——比尔·盖茨

The full inside story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers.
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work.
A riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley.

Review
"You will not want to put this riveting, masterfully reported book down. No matter how bad you think the Theranos story was, you'll learn that the reality was actually far worse."—Bethany McLean

"Carreyrou blends lucid descriptions of Theranos’s technology and its failures with a vivid portrait of its toxic culture and its supporters’ delusional boosterism. The result is a bracing cautionary tale about visionary entrepreneurship gone very wrong."—Publishers Weekly

生物科技新创公司Theranos宣称，自家公司研发的机器只需要几滴血，就可以验出许多种疾病，此研究推翻了过往血液测量的方式。与传统的血液检测动辄数百美元的花费相比，Theranos只需要2.99美元。

社会各界对于这一“颠覆性”创新十分看好，各种头衔纷至沓来：女版“乔布斯”、美女创业者；2014年底，公司的估值达90亿美元，Theranos被评为仅次于特斯拉的“改变世界的创业公司”。

似乎，这一局Theranos稳赢了。但一切的美梦都随着《华尔街日报》的调查报告而变得粉碎，Holmes的传奇故事戛然而止……

约翰·卡雷鲁，《华尔街日报》调查记者，曾两度获得普立策新闻奖。他对希拉洛斯的深入报导，获得了乔治·波克奖财经报导奖项、罗布杰出商业财经新闻奖的专题报导奖项，以及巴莱特&史提尔调查新闻银奖。《坏血》是他的第1本著作，发表后获得包括金融时报与麦肯锡年度商业书籍在内的多项大奖，并售出近20国的翻译版权。卡雷鲁目前与妻子、三名子女住在纽约布鲁克林。

John Carreyrouis a two-time Pulitzer Prize-winning investigative reporter at The Wall Street Journal. For his extensive coverage of Theranos, Carreyrou was awarded the George Polk Award for Financial Reporting, the Gerald Loeb Award for Distinguished Business and Financial Journalism in the category of beat reporting, and the Barlett & Steele Silver Award for Investigative Business Journalism. Carreyrou lives in Brooklyn with his wife and three children.

Tim Kemp had good news for his team.

The former IBM executive was in charge of bioinformatics at Theranos, a startup with a cutting-edge blood-testing system. The company had just completed its first big live demonstration for a pharmaceutical company. Elizabeth Holmes, Theranos’s twenty-two-year-old founder, had flown to Switzerland and shown off the system’s capabilities to executives at Novartis, the European drug giant.

“Elizabeth called me this morning,” Kemp wrote in an email to his fifteen-person team. “She expressed her thanks and said that, ‘it was perfect!’ She specifically asked me to thank you and let you all know her appreciation. She additionally mentioned that Novartis was so impressed that they have asked for a proposal and have expressed interest in a financial arrangement for a project. We did what we came to do!”

This was a pivotal moment for Theranos. The three-year-old startup had progressed from an ambitious idea Holmes had dreamed up in her Stanford dorm room to an actual product a huge multinational corporation was interested in using.

Word of the demo’s success made its way upstairs to the second floor, where senior executives’ offices were located.

One of those executives was Henry Mosley, Theranos’s chief financial officer. Mosley had joined Theranos eight months earlier, in March 2006. A rumpled dresser with piercing green eyes and a laid-back personality, he was a veteran of Silicon Valley’s technology scene. After growing up in the Washington, D.C. area and getting his MBA at the University of Utah, he’d come out to California in the late 1970s and never left. His first job was at chipmaker Intel, one of the Valley’s pioneers. He’d later gone on to run the finance departments of four different tech companies, taking two of them public. Theranos was far from his first rodeo.

What had drawn Mosley to Theranos was the talent and experience gathered around Elizabeth. She might be young, but she was surrounded by an all-star cast. The chairman of her board was Donald L. Lucas, the venture capitalist who had groomed billionaire software entrepreneur Larry Ellison and helped him take Oracle Corporation public in the mid-1980s. Lucas and Ellison had both put some of their own money into Theranos.